Shukla Sanjay — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Shukla Sanjay is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $4K.
Profile
Sanjay Shukla is the President and Chief Executive Officer of aTyr Pharma Inc., a biotherapeutics company that develops first-in-class medicines from the tRNA synthetase platform. The 2026-01-09 SEC filing (CIK 0001671026) lists him in the CEO role with no reported stock purchases or sales in that filing, indicating active leadership of the company at that time. He is responsible for the company's strategic direction and executive management, including oversight of clinical development efforts around efzofitimod.
Role
Insider
Notability
55/100
Board memberships
aTyr Pharma Inc.
Awards & honors
Leading aTyr Pharma's strategic direction and executive management as CEO
Overseeing development efforts around efzofitimod targeting NRP2
Sanjay Shukla is the President and Chief Executive Officer of aTyr Pharma Inc., a biotherapeutics company that develops first-in-class medicines from the tRNA synthetase platform. The 2026-01-09 SEC filing (CIK 0001671026) lists him in the CEO role with no reported stock purchases or sales in that filing, indicating active leadership of the company at that time. He is responsib…
Has Shukla Sanjay been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($4K) across all tracked filings.
Where can I see all of Shukla Sanjay's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
